Sophie Papa

Table S3 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

Figure S5 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

Figure S1 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

Figure S3 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

Table S2 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

Table S1 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

Figure S2 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

Figure S4 from Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors

Adam J. Schoenfeld, Sylvia M. Lee, Bernard Doger de Spéville, Scott Gettinger et autres

CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients

M.E. COOK, Ellen King, Katie R Flaherty, Sophie Papa et autres

gb (code pays fourni par la source)

Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma

Zena Willsmore, Lucy H. Booth, Akshay J. Patel, Ashley Di Meo et autres

gb, ca, us (code pays fourni par la source)

Abstract CT058: Final results of a first-in-human (FIH) study of intratumoral pan-ErbB-targeted CAR-T cell therapy for head and neck squamous cell carcinoma (HNSCC): T4 immunotherapy

Cienne Morton, Sophie Papa, Antonella Adami, Michael Metoudi et autres

gb (code pays fourni par la source)

Cancer immunotherapy

Charlotte O'Brien‐Gore, Sophie Papa, Shahram Kordasti

gb (code pays fourni par la source)